Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 14Phase 1 12Phase 3 5Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 5Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 4Etoposide 4Whole-Body Irradiation 2Gemcitabine 2Cyclophosphamide 2umbralisib 1ublituximab 1rasburicase 1pegfilgrastim 1fludarabine phosphate 1fludarabine 1epratuzumab 1aldesleukin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Thiotepa 1Radioimmunodetection 1Prednisone 1Oxaliplatin 1Nivolumab 1Melphalan 1Leucovorin 1Lenalidomide 1Immunoglobulins, Intravenous 1Hizentra 1Filgrastim 1Doxorubicin 1Cytarabine 1Ciprofloxacin 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Non-Hodgkin × Lenalidomide × Clear all
NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡